Testing treatments for Crimean-Congo hemorrhagic fever
Treatments studied
Part of Infections clinical trials.
This trial tests different treatments for Crimean-Congo hemorrhagic fever (CCHF), a serious viral infection. It aims to find which treatment is safe and works best for patients who are hospitalized with the disease.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older
- You are currently in the hospital for CCHF
- You have a positive lab test for CCHF within the last 5 days
- You started having symptoms within the last 7 days
- You are not pregnant or breastfeeding
- You do not have severe kidney problems or need dialysis
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial is testing an investigational RNA vaccine to see if it is safe and helps your body build immunity against Crimean-Congo hemorrhagic fever, a serious viral disease. The study involves two injections and follow-up visits over several months.
This trial is developing a quick, point-of-care diagnostic test for Crimean-Congo hemorrhagic fever (CCHF), a serious viral illness. If you have symptoms and are being tested for CCHF, this study could help confirm the diagnosis faster.
This trial tests whether Codivir can help people hospitalized with moderate COVID-19 recover better than a placebo (inactive pill). It will compare outcomes while participants receive standard hospital care.
This early-stage study tests COVID-19 treatments in people who have recently developed symptoms and who test positive for the virus. It aims to find safer, more effective options for preventing worsening disease, especially in higher-risk groups.
This trial tests different experimental drugs to treat dengue early. It aims to find which treatment works best and is safe for patients who start within 48 hours of fever.
This study looks at how hemorrhagic fever with renal syndrome (a viral infection that can cause bleeding and kidney problems) affects the body's ability to clot blood. The findings may help improve care for patients with this condition.
Hear when a new Crimean-Congo Hemorrhagic Fever trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.